Ketamine: Catalyst for Paradigm Change in Mental Health

Ketamine: Catalyst for Paradigm Change in Mental Health

Why this matters

• Our current mental-health model isn’t meeting the moment; outcomes for depression, suicide, and “deaths of despair” remain alarming [1–10].
• Psychedelic-assisted care offers a different, more integrative path. Among today’s legal options, ketamine uniquely bridges conventional psychiatry with a holistic, person-centered model of healing [26–36].
• Used thoughtfully—with preparation, set/setting, and integration—ketamine can relieve symptoms rapidly, deepen psychotherapy, and catalyze durable change [28–33, 59–67].

The problem we’re trying to solve

Despite decades of antidepressant prescribing, suicide rates have climbed ~30% over the last two decades, fewer than half of people respond to a first antidepressant, and a large share develop treatment-resistant depression [1–3, 6]. The pandemic intensified an already-fragile system—especially for teens and healthcare workers [7–10]. We need a care model that goes beyond symptom suppression. [1–10].

Where ketamine fits in

Ketamine offers a practical, legal path toward an evocative model of care—one that honors the psyche rather than numbing it. It can work rapidly (hours to days), does not require daily dosing, and can be paired with psychotherapy to accelerate insight and change [26–33]. Its effects on the default mode network and neuroplasticity help “unstick” rigid patterns of thought and behavior, creating a window of opportunity for growth [29, 42–43, 63–66].

Why this is a paradigm shift (not just another medication)

• From suppression to engagement. Traditional pharmacology often mutes distress; ketamine can invite transformative inner work within a safe container [18–21, 26–33].
• Therapy-forward. Ketamine is most powerful when framed by preparation and integration, making psychotherapy more effective rather than replacing it [22–25, 40].
• Integrative by design. Outcomes improve when we address lifestyle, relationships, trauma, and meaning—alongside biology [25–29].

Ketamine, at a glance

• Rapid relief and strong effect sizes even in medication-refractory depression [26, 31–33].
• Episodic dosing (not daily) with room to individualize experience intensity (from psycholytic to fully immersive) [28, 65–67].
• Generally well-tolerated at psychiatric doses with a long track record in anesthesia and pain care [33–36, 39–41].
• Compatible with many psychiatric meds (often no lengthy washout required) [53–55].
• Accessible and scalable in clinic settings; medicine cost is low (most cost relates to trained clinician time and therapeutic support) [56–58].

What the experience can feel like

Sessions are time-bounded (typically under ~2–3 hours door-to-door, with 40–60 minutes of altered consciousness), with effects ranging from gentle softening to profound, non-ordinary states of awareness. The dissociative quality can reduce emotional overwhelm, which helps trauma work proceed without re-traumatization [39–51, 67–69]. Preparation and integration turn insights into real-world change [22–25, 59–67].

What ketamine is not

Ketamine is a tool—not a full system of care. It won’t replace therapy, community, or changes in sleep, nutrition, movement, and relationships. It’s also not appropriate for every presentation; comprehensive assessment and an integrative plan remain essential [23–29].

The path forward

As MDMA and psilocybin move through regulatory pathways, ketamine is here now—and it can train clinicians, build therapeutic skill, and help patients today. Thoughtful, ethical ketamine-assisted care lets medication and psychotherapy finally pull in the same direction: toward healing, meaning, and renewed capacity to thrive [35–36, 44–52, 59–71].

Ready to explore whether ketamine therapy is right for you?

Click to speak with our wellness care team today.

References

1. CDC. Data Brief 433. https://www.cdc.gov/nchs/products/data-briefs/db433.htm.
2. Alemi F, Min H, Yousefi M, et al. EClinicalMedicine. 2021;41:101171. doi:10.1016/j.eclinm.2021.101171.
3. Zhdanava M, Pilon D, Ghelerter I, et al. J Clin Psychiatry. 2021;82(2):20m13699. doi:10.4088/JCP.20m13699.
4. CDC. Data Brief figure (1999–2017). https://www.cdc.gov/nchs/images/data-briefs/351-400/db362-fig1.png.
5. CDC YRBS 2023 Summary. https://www.cdc.gov/healthyyouth/data/yrbs/pdf/YRBS_Data-Summary-Trends_Report2023_508.pdf.
6. Whitney DG, Peterson MD. JAMA Pediatr. 2019;173(4):389–391. doi:10.1001/jamapediatrics.2018.5399.
7. Arias D, Saxena S, Verguet S. EClinicalMedicine. 2022;54:101675. doi:10.1016/j.eclinm.2022.101675.
8. Ettman CK, Cohen GH, Abdalla SM, et al. Lancet Reg Health Am. 2022;5:100091. doi:10.1016/j.lana.2021.100091.
9. Burrowes SAB, Casey SM, Pierre-Joseph N, et al. J Interprof Educ Pract. 2023;32:100661. doi:10.1016/j.xjep.2023.100661.
10. Yard E, Radhakrishnan L, Ballesteros MF, et al. J Psychiatr Res. 2021;139:61–72. doi:10.1016/j.jpsychires.2021.02.058.
11. Van W, Schwartz JM. Front Psychiatry. 2021;12:579566. doi:10.3389/fpsyt.2021.579566.
12. Ban TA. Dialogues Clin Neurosci. 2006;8(3):335–44. doi:10.31887/DCNS.2006.8.3/tban. allpsychedelichealth.com
13. Pratt LA, Brody DJ, Gu Q. NCHS Data Brief, No. 283 (2017). https://www.cdc.gov/nchs/products/databriefs/db283.htm.
14. PsychCentral. Top 25 psychiatric medications (2020). https://psychcentral.com/blog/top-25-psychiatric-medications-for-2020#top-25-list.
15. Patteson SE. Epidemiol Psychiatr Sci. 2015;24(4):303–8. doi:10.1017/S2045796015000153.
16. Nutt D. The Conversation/ScienceX. https://www.sciencex.com/news/2021-07-chemical-imbalance-explain-depression/.
17. Moncrieff J, Cooper RE, Stockmann T, et al. Mol Psychiatry. 2022;27:4037–4046. doi:10.1038/s41380-022-01808-2.
18. Timmermann C, Kettner H, Letheby C, et al. Sci Rep. 2021;11:221160. doi:10.1038/s41598-021-01209-2.
19. Sweeney MM, Nayak S, Hurwitz ES, et al. PLoS One. 2022;17(8):e0271926. doi:10.1371/journal.pone.0271926.
20. Sloshower J, Skosnik PD, Saffi-Aghdam H, et al. J Psychopharmacol. 2023;37(6):745–759. doi:10.1177/02698811231154852.
21. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Sci Rep. 2017;7:13187. doi:10.1038/s41598-017-13282-7.
22. FDA Breakthrough Therapy designations (psilocybin/MDMA). https://www.medscape.com/viewarticle/921789.
23. MAPS/Mitchell JM, Bogenschutz M, et al. Nat Med. 2021;27:1025–1033. doi:10.1038/s41591-021-01336-3.
24. Effect sizes for MDMA vs conventional meds. https://www.empr.com/home/news/drugs-in-the-pipeline/phase-3-trial-evaluating-mdma-assisted-therapy-for-ptsd-meets-endpoints/.
25. FDA (2023) esketamine news. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified.
26. Andrade C. J Clin Psychiatry. 2017;78(4):e415–e419. doi:10.4088/JCP.17f11738.
27. Janssen/Spravato approval (2019). https://www.empr.com/home/news/drugs-in-the-pipeline/phase-3-trial-evaluating-mdma-assisted-therapy-for-ptsd-meets-endpoints/ (see Spravato note).
28. Hitenimus TM, Melchnes LA, Kimes AJ, et al. J Affect Disord. 2023;335:484–492. doi:10.1016/j.jad.2023.04.141. allpsychedelichealth.com
29. Li M, Woelfer M, Colic L, et al. Eur Arch Psychiatry Clin Neurosci. 2020;270(2):207–216. doi:10.1007/s00406-018-0942-y.
30. Hirschfeld T, Prueger J, Majić T, Schmidt TT. Neuropsychopharmacology. 2023;May 9. doi:10.1038/s41386-023-01588-2.
31. Tsang VWL, Tao B, Dames S, et al. J Affect Disord. 2022;May:137:232–241. doi:10.1016/j.jad.2022.02.125.
32. Oughli HA, Gebara MA, Ciarloglio A, et al. J Geriatr Psychiatry Neurol. 2023;36(1):210–221. doi:10.1177/08919887221175112.
33. Smith-Apeldoorn SY, Veraart JK, Spijker J, et al. Lancet Psychiatry. 2022;9(11):907–921. doi:10.1016/S2215-0366(22)00317-0.
34. Abdallah CG, Roache JD, Gueorguieva R, et al. Neuropsychopharmacology. 2022;47(8):1574–1584. doi:10.1038/s41386-022-01266-9.
35. Tamman A, Anand A, Mathew SJ. Expert Opin Drug Saf. 2022;21(6):745–759. doi:10.1080/14740338.2022.2049754.
36. Di Vincenzo JD, Siegel A, Lipsitz O, et al. J Psychiatr Res. 2022;May:137:232–241. doi:10.1016/j.jpsychires.2021.02.058.
37. Carhart-Harris RL, Friston KJ. Brain. 2010;133(4):1265–83. doi:10.1093/brain/awq010.
38. Abdallah CG, Ahn KH, Averill LA, et al. Neuropsychopharmacology. 2021;46(2):479–485. doi:10.1038/s41386-020-00864-9.
39. NCBI Bookshelf: Ketamine (pharmacology). https://www.ncbi.nlm.nih.gov/books/NBK47035/.
40. Levine S. “Reflections on 10,000 administrations of ketamine.” Kriya Ketamine Conference (2017). https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-march-2022/. allpsychedelichealth.com
41. Kopelman J, Keller ZA, Panny B, et al. Transl Psychiatry. 2023;13(1):159. doi:10.1038/s41398-023-02451-0.
42. Shaw AD, Muthukumaraswamy SD, Saxena N, et al. Neuroimage. 2020;221:117189. doi:10.1016/j.neuroimage.2020.117189.
43. Garcia-Romeu A, Richards WA. Int Rev Psychiatry. 2018;30(4):291–316. doi:10.1080/09540261.2018.1486289.
44. Yuan S, Luo X, Chen X, Wang M, et al. J Affect Disord. 2023;Jan:1:320–329. doi:10.1016/j.jad.2022.09.125. allpsychedelichealth.com
45. Can AT, Hermens DF, Mohamed AZ, et al. J Affect Disord. 2023;Jun 15:331:92–100. doi:10.1016/j.jad.2023.03.064.
46. Lamanna J, Iotti F, Ferro M, et al. Sci Rep. 2022;12(1):11055. doi:10.1038/s41598-022-14694-w.
47. Wade BSC, Loureiro J, Sahib A, et al. Psychol Med. 2022;52(12):2376–2386. doi:10.1017/S0033291722001313.
48. Horeck J, Bruns U, Brousnyk N, et al. Psychol Med. 2020;50(9):1443–51. doi:10.1017/S0033291719000619.
49. Doss MK, Madden MB, Gaddis A, et al. Brain. 2020;143(8):2411–456. doi:10.1093/brain/awaa046.
50. Gattuso JJ, Perkins D, Ruffell S, et al. J Neuropsychopharmacol. 2023;Mar 22:29(6):155–188. doi:10.1093/ijnp/pyac074.
51. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Sci Rep. 2017;7:13187. (fMRI study).
52. Carhart-Harris RL, Muthukumaraswamy S, et al. PNAS. 2012;109(26):11044–49.
53. Ait Benitake K, Boisvert M, Tourignon V, et al. J Psychoactive Drugs. 2023;May 15:1–14. doi:10.1080/02791072.2023.2109758.
54. Uhlhaas PJ, Singer W. Nat Rev Neurosci. 2010;11(2):100–13. doi:10.1038/nrn2774.
55. Hunt T, Schooler JW. Front Hum Neurosci. 2019;13:378. doi:10.3389/fnhum.2019.00378.
56. Tonello L, Cocchi M, Gabrielli F, et al. Med Hypotheses. 2017;101:78–84. doi:10.1016/j.mehy.2017.02.013.
57. Cavanna AE, Nenna C, Mangiatordi P, et al. Prog Neurobiol. 2015;134:54–70. doi:10.1016/j.pneurobio.2015.09.004.
58. Nicolaou N, Georgiou J. Br J Anaesth. 2014;112(3):529–39. doi:10.1093/bja/aet350.
59. Lutz A, Greischar LL, Rawlings NB, et al. Proc Natl Acad Sci USA. 2004;101(46):16369–73. doi:10.1073/pnas.0407401101.
60. Nagy D, Stoiljkovic M, Menniti FS, et al. Neuropsychopharmacology. 2016;41(6):1486–94. doi:10.1038/npp.2015.298.
61. Nugent AC, Ballard ED, Gould TD, et al. Mol Psychiatry. 2019;24(7):1040–1052. doi:10.1038/s41380-018-0082-8. allpsychedelichealth.com
62. Purdon PL, Sampson A, Pavone KJ, Brown EN. Anesthesiology. 2015;123(4):937–60. doi:10.1097/ALN.0000000000000841.
63. Zacharias N, Musso F, Müller F, et al. Hum Brain Mapp. 2020;Jan:1–19. doi:10.1002/hbm.24791.
64. Greyson B. J Nerv Ment Dis. 2022;Sep:1;210(9):692–696. doi:10.1097/NMD.0000000000000521.
65. Kopeil J. Proc (Bayl Univ Med Cent). 2019;Jan 11;32(1):163–164. doi:10.1080/08998280.2018.1542478.
66. Marsili C, Saccà F, Charland-Verville V, et al. Conscious Cogn. 2019;69:52–69. doi:10.1016/j.concog.2019.01.019.
67. Le TT, Cordero JP, Jawad MY, Swainson J, et al. J Psychiatr Res. 2023;May 10. doi:10.1016/j.jpsychires.2022.04.035.
68. Orhurhu OV, Vashisht R, Claus LE, Cohen SP. StatPearls (2023). https://www.statpearls.com.
69. Chan EOT, Chan VWS, Tang TST, et al. Hong Kong Med J. 2022;Dec:28(6):466–474. doi:10.12809/hkmj209194.
70. The New York Times (2023). https://www.nytimes.com/2023/02/20/us/ketamine-telemedicine.html.
71. HealingMaps: Psilocybin laws (CO vs OR). https://healingmaps.com/psilocybin-laws-colorado-oregon-differences/.

Adapted (for clarity, readability, and SEO) from Scott Shannon, M.D. FAACAP: “Ketamine: Catalyst for Paradigm Change in Mental Health,” Journal of Psychedelic Psychiatry 5(2) (2023). Full text and references in the PDF above. allpsychedelichealth.com
Original Daydream MD article page: “Ketamine: Catalyst for Paradigm Change in Mental Health.”

‍